The medicines regulator has told patients to return Emerade 300 and 500 microgram adrenaline pens over fears some may fail to or prematurely activate if dropped.
Patients, or carers of patients, should "immediately" contact their GP, obtain a prescription for, and be supplied with, an alternative brand before returning the Emerade auto-injector pens, the Medicines and Healthcare products Regulatory Agency said.
Data from medical experts Open Prescribing, shared by the regulator, shows the Emerade pens were prescribed 20,256 times in England between March 2022 and February 2023.